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The interest of 18Fluoro-deoxyglucose (FDG) positron emission tomography (PET)
imaging in the management of patients with multiple myeloma (MM) for the workup at
diagnosis and for therapeutic evaluation has recently been demonstrated. FDG-PET is a
powerful imaging tool for bone lesions detection at initial diagnosis with high sensitivity
and specificity values. The independent pejorative prognostic value on progression-free
survival (PFS) and overall survival (OS) of baseline PET-derived parameters (presence
of extra-medullary disease (EMD), number of focal bone lesions (FLs), and maximum
standardized uptake values [SUVmax]) has been reported in several large independent
prospective studies. During therapeutic evaluation, FDG-PET is considered as the
reference imaging technique, because it can be performed much earlier than MRI
which lacks specificity. Persistence of significant FDG uptake after treatment, notably
before maintenance therapy, is an independent pejorative prognostic factor, especially
for patients with a complete biological response. So FDG-PET and medullary flow
cytometry are complementary tools for detection of minimal residual disease before
maintenance therapy. However, the definition of PET metabolic complete response
should be standardized. In patients with smoldering multiple myeloma, the presence
of at least one hyper-metabolic lytic lesions on FDG-PET may be considered as a
criterion for initiating therapy. FDG-PET is also indicated for initial staging of a solitary
plasmacytoma so as to not disregard other bone or extra-medullary localizations.
Development of nuclear medicine offer new perspectives for MM imaging. Recent PET
tracers are willing to overcome limitations of FDG. (11)C-Methionine, which uptake
reflects the increased protein synthesis of malignant cells seems to correlate well with
bone marrow infiltration. Lipid tracers, such as Choline or acetate, and some peptide
tracers, such as (68) Ga-Pentixafor, that targets CXCR4 (chemokine receptor-4, which
is often expressed with high density by myeloma cells), are other promising PET ligands.
18F-fludarabine and immuno-PET targeting CD138 and CD38 also showed promising
results in preclinical models.
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INTRODUCTION
Multiple myeloma (MM) is a hematological neoplasm
characterized by the clonal proliferation of malignant plasma
cells in the bone marrow. It is almost always preceded by an
initial monoclonal gammopathy of undetermined significance
(MGUS), that then develops into asymptomatic or Smoldering
MM (SMM), which constitutes an intermediate clinical stage
between MGUS and MM.
The rate of progression from MGUS to MM is 0.5–
1% per year, and that of SMM to MM 10% per year for
the first 5 years, with the thresholds of serum M protein
and spinal plasmacytosis differing between both classifications.
SMM is a heterogeneous classification including patients with
a very slow progression to proven MM (several years) and
patients progressing very rapidly to symptomatic MM in
<2 years (high-risk SMM). The definition of symptomatic
MM, a clinical stage requiring treatment, typically based on
the presence of CRAB criteria (HyperCalcemia, Renal failure,
Anemia, and Bone disease) (1) was revised in 2014 by the
International Myeloma Working Group (IMWG) by integrating
new prognostic biomarkers (2), with the aim of not delaying
the initiation of treatment for patients classified as high risk
SMM and to avoid progression to harmful bone lesions or renal
insufficiency. Indeed, medullary plasmacytosis≥60%, serum free
light chain ratio ≥100 and more than 1 focal MRI bone lesion
were predictive of an 80% progression to a CRAB-positive MM
within 2 years in several studies, confirming a stage of the disease
requiring treatment.
In addition, the 2014 IMWG criteria for the diagnosis
of MM highlighted the importance of new imaging in the
management of MM in order to detect bone disease, which is
considered as a symptomatic MM criterion requiring treatment
even when asymptomatic. Studies conducted over the past 10
years have shown better performance using low-dose whole-body
CT and MRI scans (3, 4) than standard skeletal radiographs,
formerly considered as the reference technique for detecting
bone disease.
Recent data suggest that positron emission tomography (PET)
using 18F-deoxyglucose (FDG) is a reliable imaging for initial
staging, therapeutic monitoring and relapse workup in MM,
especially because of its prognostic potential (5). Moreover, as
shown recently in a prospective comparison between size of
biopsied focal bone lesions (FL) depicted by FDG-PET and
genomic profiles, the extent of spatial heterogeneity is positively
associated with the size of FL, resulting coexistence of different
disease clones (6). More recent PET tracers (Methionine, lipid
and peptide tracers) are available to overcome limitations of FDG.
PERFORMANCE OF FDG-PET FOR THE
DETECTION OF MEDULLARY AND
EXTRA-MEDULLARY DISEASE AT
INITIAL DIAGNOSIS
PET-FDG allows whole-body exploration and has a global
sensitivity of 90% for the detection of medullary disease with
a specificity varying from 70 to 100% according to several
studies (7–9). Medullary abnormalities detected by PET are
focal lesions (Figure 1), para-medullary lesions (PML, Figure 2)
and diffuse medullary involvement with variable glucose uptake,
resulting in variable SUVmax values (5–13). FDG-PET also allows
the detection of extra-medullary disease (EMD, Figure 3), in
<10% of patients at diagnosis (14). FL are most often defined
as foci of uptake above the surrounding background noise
on two successive sections with or without osteolysis opposite
the CT image. PML are soft tissue invasions with contiguous
bone involvement. Diffuse bone marrow involvement is usually
defined as heterogeneous or homogenous diffuse uptake of
the axial (that may extend to the peripheral) skeleton, of
greater intensity than the liver (Figure 4). MM related disease
abnormalities to be incorporated in the baseline FDG-PET report
are presented in the Table 1.
The Bologna group recently proposed the “IMPETUS”
criteria (15) to standardize the interpretation of PET in MM.
It showed that the use of a standardized visual scale of
interpretation (Deauville 5-level scale) in the description of the
number of FL, EMD as well as diffuse medullary involvement
makes it possible to improve the reproducibility of inter-
observer interpretation (with however, a very great disparity
in interpretation of skull lesions). The pathological positivity
cut-offs for bone lesions, especially on therapeutic evaluation
examinations, are still to be determined however, especially
when comparing with sensitive biological techniques (CMF) for
detection of MRD.
The sensitivity of FDG-PET is greater than whole-body
radiology to detect bone lesions and comparable to or less than
that of pelvic-spinal MRI (7, 12, 16–19). In the first small series
of patients comparing FDG-PET and MRI, sensitivity of FDG-
PET was less than that of pelvic-spinal MRI (PR-MRI) for diffuse
medullary involvement but allowed detection of additional FL,
especially outside the field of the MRI view (17). More recently,
the French Imajem study (14) prospectively compared PR-MRI
and FDG-PET at initial diagnosis and after therapy. In this cohort
of 134 patients with symptomatic MM, PR-MRI was positive
in 94.7% of cases and FDG-PET in 91% of cases, revealing an
equivalent detection sensitivity.
FDG-PET also demonstrated interest in patients with solitary
plasmacytoma (SP), allowing detection of additional lesions,
with sensitivity, and specificity greater than MRI (5–7, 20). In
addition, Fouquet et al. showed that the presence of at least
2 hypermetabolic lesions by FDG-PET was predictive of rapid
progression to MM (21).
According to recent update data of the Southeastern
Minnesota cohort (22) with a long-term follow-up, there are
adversely risk factors for MGUS to active MM progression
including an M-protein of 15 g/L or more and an abnormal
free light chain ratio in patients with non-IgM MGUS. Patients
with 2 risk factors showed a significantly higher progression
rate to MM of 30% in 20 years than patients with no
(7%) or 1 risk factor (20%). Therefore, there is a need of
imaging for patients with high risk MGUS. To date, there
are unfortunately no published data on FDG-PET findings in
MGUS patients.
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FIGURE 1 | Patient with more than 10 focal lesions of the axial and appendicular skeleton. Note absence of osteolysis on opposite CT scan of right femur focal lesion.
FIGURE 2 | Voluminous hypermetabolic lytic lesion of the right femoral shaft contiguously invading adjacent soft tissues.
PROGNOSTIC VALUE OF FDG-PET IN
SMM AND SYMPTOMATIC MM AT
BASELINE EVALUATION
FDG-PET showed prognostic value in patients with SMM and
symptomatic MM.
Even if the latest international recommendations of the
IMWG (1) indicate that the presence of one or more FL with
osteolysis on FDG-PET is considered a criterion for treatment
at initial diagnosis, all prospective studies lead from 2009 defined
FL as foci of uptake with or without osteolysis cause metabolic
could precede morphological abnormalities.
Moreover, in SMM, a positive FDG-PET defined by the
presence of FL without underlying osteolytic lesions is associated
with a rapid progression to symptomatic MM. Indeed, in
a cohort of 122 SMM patients, Siontis et al. (23) showed
that the probability of progression to MM within 2 years for
positive FDG-PET patients was 75 vs. 30% for patients with
a negative PET, without therapy. In another prospective study
of 120 SMM patients, the group of Bologna (24) reported a
rate of progression to symptomatic MM at 2 years of 58%
for patients with positive PET vs. 33% for patients with a
negative PET.
In symptomatic MM baseline evaluation, three large
prospective studies have demonstrated important prognostic
impact of FDG-PET results, which is particularly important
at age of precision medicine and risk-based therapies. First of
all, Bartel et al. in a large cohort (n = 239) treated using the
Total Therapy 3 strategy (25) showed that the only imaging
examination (between FDG-PET and MRI) significantly
associated with an adverse prognosis for both overall survival
(OS) and event-free survival (EFS) was FDG-PET when the
number of FL was >3. Then, the Bologna group, in a large
series of 192MM patients also enrolled in a double autologous
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FIGURE 3 | Extra-medullary disease histologically proven in this subcutaneous mass.
FIGURE 4 | Diffuse medullary involvement (and superimposed lesions).
stem cell transplantation (ASCT) program after induction (26),
confirmed the pejorative prognostic impact of more than 3 FL
on progression-free survival (PFS) at 4 years as well as an SUV
> 4.2 and the presence of EMD. SUV > 4.2 and the presence
of EMD were also associated with a shorter OS. The prognostic
value of EMD on PFS and OS was recently confirmed by the
French Imajem study (14).
Two large retrospective studies found equal results about
prognostic value of FDG-PET in symptomatic MM baseline
evaluation. The Mayo Clinic team, in a 313 patient cohort
showed that the presence of at least 3 FL and EMD predicted
inferior OS (only by univariate analysis), with no clear SUVmax
cutoff predictive of PFS or OS (27). In a smaller series of
patients (n = 167), Jung et al. (28) confirmed (in multivariate
analyses) that presence of more than three FL or EMD was
associated with significantly inferior PFS and OS, especially in
Revised International Staging System (R-ISS) II and III subgroups
of patients.
More complex PET biomarkers, such as functional volumes
and tumor heterogeneity, have also been studied or are
being evaluated with promising results. First pre-therapeutic
assessment of the whole-body total metabolic volume of FL and
EMD (MTVWB) in 47 patients showed a poor prognostic value
of high values on PFS and OS (29), with best discriminant cut-
offs of 42.2 cm3 for the PFS and 77.6 cm3 for the OS. A second
larger study of 192 patients confirmed the poor prognostic value
of a high MTVWB, which was also similar for a high Total
lesion glycolysis (TLG)WB (30). Indeed, bymultivariate analysis,
TLGWB> 620 g or MTVWB> 210 cm3 at baseline significantly
decreased PFS and OS after adjustment for known prognostic
factors. Combined with the gene expression profiling prognostic
score (GEP70), a TLGWB> 205 g identified a high-risk subgroup
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TABLE 1 | What should be provided in the FDG-PET report at baseline?
MM related disease abnormalities
• Focal Lesion (FL): With or without osteolysis on CT: Total Number: 0, 1–3, >3;
Intensity: Hottest SUVmax (Most intense FDG uptake identified among all foci
determined by the nuclear physician);
• Bone Marrow diffuse involvement (BMI): Evaluation of the bone marrow
diffuse uptake, regardless focal lesions: Visual analysis (Deauville 5-level scale):
Positive if diffuse uptake of the axial (that may extend to the peripheral) skeleton
is greater intensity than the liver (Deauville 4 or 5).
• Extramedullary disease (EMD): Soft tissue or nodal mass not directly adjacent
to MM bone localization: Presence or not and localization.
• Paramedullary disease (PMD): Bone lesion involving surrounding soft tissues
with bone cortical interruption: Presence or not, localization, clinical risk?
MM, multiple myeloma; CT, computed tomography; SUV, standardized uptake value.
and separated ISS II patients into two subgroups, with a similar
outcome to ISS I and ISS III patients.
Finally, as described by Carlier et al. (31) for 66 patients of
the Imajem study, intra-tumoral textural features (e.g., reflecting
of tumor heterogeneity), especially energy, also seem to be of
prognostic value (independent prognostic value of energy on PFS
and OS). More work is in progress on this subject.
PROGNOSTIC VALUE OF FDG-PET IN
THERAPEUTIC EVALUATION
FDG-PET is considered as the reference imaging technique
for therapeutic evaluation in MM with a strong independent
prognostic value (5). FDG-PET allows evaluation of the response
earlier than standard MRI but new MRI functional approaches,
such as diffusion weighted imaging (DWI) measuring the
apparent diffusion coefficient (ADC) influenced by tissue
microarchitecture and related to marrow cellularity could be
interesting tools to evaluate the disease after therapy (32, 33).
However, homogeneous and prospective data about comparison
between FDG-PET and WB-DWIMRI are lacking (34).
FDG-PET, coupled with a biological technique for the
detection of minimal residual disease (MRD), makes it possible
to improve the definition of complete response (35) clearly
correlated with long-term outcomes.
All large prospective studies above mentioned have
demonstrated the strong and independent prognostic impact of
FDG-PET results after therapy of symptomatic MM.
The Little Rock team first showed in 2009 that normalization
of FDG uptake of FL after chemotherapy induction cycles (before
the transplant procedure) was associated with better EFS and
OS (25). The same team reported in 2013 in a larger series
of 302 patients (277 of them were also the object of a gene
expression profile study) (36) treated according to the same
intensive protocol that 3 FL on FDG-PET performed at Day 7
of induction was associated with lower PFS and OS, even in the
high-risk group in relation to genetic profiling. FDG-PET could
be considered as a tool for early therapeutic adaptation. They
finally confirmed these results in 2018 from data collected in
their TT4–TT6 clinical trials, in a very large cohort of more than
500 patients, showing patients achieving 100% suppression of FL
signal following treatment at each time point studied (day 7, end
of induction, post transplantation, and maintenance) had PFS
andOS values that were not significantly different from cases with
no FL present at baseline (37).
The Bologna group then showed that after induction therapy,
a SUV > 4.2 was associated with a reduced PFS (26). Three
months after ASCT, complete metabolic response (CMR) was
achieved in 65% of patients, with PFS and OS at 4 years higher
than those in PET-positive patients. Interestingly, 23% of patients
achieving CR in accordance with conventional criteria were
considered PET-positive. Multivariate analysis showed that post
ASCT PET status was an independent prognostic factor of PFS.
In 2015, the same group confirmed these results in 282 patients
undergoing front line treatment between 2002 and 2012 (38).
After treatment, a CMR was obtained in 70% of patients, whereas
the conventional biological methods concluded at 53% of CR.
The FDG-PET negativity affected the PFS and the OS positively.
The Imajem study more recently confirmed the major
benefit of FDG-PET in therapeutic evaluation (14). Whereas,
normalization of MRI after three cycle of combined induction
therapy or before maintenance did not significantly affect either
PFS or OS, FDG-PET normalization before maintenance was
strongly associated with better PFS and OS. The PFS and OS
of PET-negative patients were better than those of PET-positive
patients (24-months PFS by 72 vs. 56.8%: p = 0.01; OS at 24
months of 94.2 vs. 72.9%: p = 0.03). In addition, multivariate
analysis revealed that normalization of pre-maintenance FDG-
PET was independently associated with longer PFS, such as
absence of EMD at diagnosis and at least a very good partial
biological response after three cycles of induction therapy.
Moreover, for the Imajem patients presenting a FDG-avid
MM defined by lesion intensity higher than liver background,
the prognostic value of FDG-PET after three cycles of induction
therapy was also reported (39). Indeed, by multivariate analysis,
only 1SUVmax (p < 0.001) and biochemical response (p =
0.025) appeared as independent prognostic factors, with a more
discriminative hazard ratio for 1SUVmax analysis (>−25 vs.
≤−25%) which identified patients with improved median PFS.
The benefit of post-ASCT FDG-PET was also reported in
2013 in a prospective series of 77 patients assessed by FDG-
PET 3 months after ASCT, and then every 6–12 months during
follow-up (40). The duration of the response was longer when
the PET scan was negative (27.6 months) than when it was
positive (18 months, p = 0.05), whereas in patients with positive
PET, SUVmax was inversely correlated with the duration of the
response (P < 0.01).
However, the definition of CMR was not the same in these
different clinical studies and a standardization of FDG-PET
interpretation criteria should be done. Definition of cut-offs for
FDG-PET positivity/negativity after therapy for MRD evaluation
is currently underway. Preliminary results of a combined analysis
of two European prospective trials have been presented by
Zamagni et al. at the 2018 annual meeting of the ASH (41).
In this joint analysis of 236 patients, attaining FL and bone
marrow Deauville score <4 prior to maintenance therapy was
the strongest independent predictor for prolonged PFS and OS
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and could be identified as the most representative cut-off value
for PET negativity after therapy. Moreover, the CASSIOPET
study is on-going, aiming to determine the best CMR threshold
(mediastinal vs. hepatic background) on FDG-PET and try to
establish the concordance between CMR and MRD negativity in
the bone marrow (by flow cytometry or sequencing) to confirm
the complementary role of functional imaging with modern
biological tools for the detection of MRD inside and outside the
bone marrow.
PROGNOSTIC VALUE OF FDG-PET AT
RELAPSE SETTING
Although existing data are less available, FDG-PET seems to have
also a prognostic impact at relapse workup. In a small series of
37MM patients suspected of relapse after ASCT, it was shown
that the absence of FL was a favorable prognostic factor for time
to progression (TTP) and OS (42). The presence of more than 10
FL correlated with a shorter TTP and OS whilst a high SUVmax
and the presence of EMD resulted in a longer TTP.
More recently, in a retrospective series of 40 confirmed
relapsed patients, Nantes’ group have described that the presence
of at least 6 FL in the peripheral skeleton was an independent
pejorative prognostic factor on both the PFS and the OS by
multivariate analysis (43). Moreover, a high SUVmax (>15.9) was
an independent negative prognostic factor on the PFS as was
a high TLG of the hottest lesion (>98.1 g). Interestingly, 15%
of the patients were FDG-PET positive without re-ascending
the monoclonal peak and no change in the level of serum free-
light chains.
Finally, scarce data on the value of FDG-PET before or after
allo-SCT are available but two retrospective studies of heavily
pre-treated MM patients showed FDG-PET results prior to and
after allo-SCTwere strongly associated with the outcome (44, 45).
NEW PET TRACERS
It has been recently reported in a 227 patients study with an
initial diagnosis of symptomatic MM a FDG-PET negativity
rate of 11% (13). It was found in this subgroup of patients
a low expression of the hexokinase 2 gene (which catalyzes
the first step of glycolysis) and consequently a FDG trapping
in the cells. Indeed, for these patients FDG-PET is not an
appropriate tool to evaluate MRD. Development of nuclear
medicine offer new perspectives for MM imaging and other
PET tracers, preliminarily investigated in limited series of
MM patients, targeting other metabolic pathways or plasma
cell receptors, could be potentially more sensitive and specific
than FDG.
11C-Methionine, which uptake reflects the increased protein
synthesis of malignant cells seems to correlate well with bone
marrow infiltration and could be more sensitive than FDG to
detect intra- and extra-medullary MM lesions (46).
Choline is a lipid PET tracer clinically used for the evaluation
of relapse of prostate cancer. This tracer labeled with C11
was proposed years ago in a preliminary study in comparison
to FDG on 10 patients affected by symptomatic MM (47)
and showed Choline would reveal more lesions. Another
study on the comparison of FDG and 18F-Choline presented
similar results on 21 patients with symptomatic MM (48).
Then it seems that Choline (either C11- or 18F-) has a better
detection rate as compared to FDG in MM patients at staging.
However, unfavorable physiological biodistribution (increased
background of the liver parenchyma and of the bone marrow)
is a limitation.
Pilot study comparing other lipid tracer (11C-Acetate) and
FDG at diagnosis of symptomatic MM also showed acetate would
reveal more lesions (49).
Another new and potentially interesting tracer is CXCR4. C
– X – C chemokine receptor 4 (CXCR4) is a G-protein-coupled
chemokine receptor family implicated in the process of cell
migration as well as in the homing process of hematopoietic stem
cells to the bone marrow, angiogenesis and cell proliferation.
In multiple myeloma, CXCR4 expression is associated to
disease progression and poor prognosis (50). Most experience
with CXCR4-directed PET imaging has been gained in MM and
around two thirds of patients could overexpress the receptor on
the myeloma cell surface.
68Ga-Pentixafor, that targets CXCR4 is a promising PET
ligand (51) especially as potential target for myeloma specific
treatment (for CXCR4-positive tumors) in a theranostic
approach with preliminary encouraging results with good
tolerance of the treatment, high initial response rates in
advanced-stage MM cases (52). However, it has been reported
that, in a non-negligible number of cases, FDG provided better
detectability so further studies would be important to clarify
this aspect (53). Moreover, receptor expression seems to be a
dynamic process that could be highly influenced by preceding or
concomitant chemotherapy (53).
18F-fludarabine (54) and immuno-PET targeting CD138
(55) and CD38 (56, 57) also showed promising results in
preclinical models.
However, pending issues with these new tracers are
willingness, inter-patient tumor heterogeneity for specific
targets and the lack of prognostic data reported.
CONCLUSION
FDG-PET is a powerful diagnostic tool for the detection of
medullary and extra-medullary disease at the initial diagnosis
of symptomatic MM with a pejorative prognostic value for
the presence of EMD. Moreover, FDG-PET is the reference
imaging technique to assess therapeutic response of symptomatic
MM, evaluation being available much earlier than by MRI.
The negativity of pre-ASCT FDG-PET is a favorable prognostic
factor and the positivity of FDG-PET after ASCT, especially in
patients with complete biological response, is an independent
pejorative prognostic factor. The negativity of FDG-PET,
intramedullary flow cytometry, and the ratio of serum free
light chains would make it possible to define an optimal
complete response (eradication of monoclonal plasma cells
in all compartments). Ongoing prospective trials will try to
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establish the concordance between CMR and MRD negativity
in the bone marrow to confirm the complementary role
of functional imaging with modern biological tools for the
detection of MRD inside and outside the bone marrow. We
recommend to perform FDG-PET at initial work-up and after
therapy (before maintenance) for detection of EMD, for patients
with oligo/non-secretory MM and if a MRD assessment is
performed. At relapse it is probably the best imaging technique
to differentiate active disease from morphological scars and
remodeling. Other PET tracers may also show interest in
FDG-negative patients but should be evaluated in prospective
clinical trials.
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